Skip to main content

Absci Corp

corporate_fare Company Profile

Absci Corp

ABSI·NASDAQ·Industrial Applications And Services·CIK 0001672688

Absci Corp is a clinical-stage biopharmaceutical company that uses an AI-native approach to develop antibody therapeutics. The company's integrated drug creation platform combines Origin-1, a generative design model, with rapid validation using its lab-in-the-loop system. Absci focuses on underexplored biological mechanisms where there is a high unmet medical need and low competition. The company has advanced its first two programs from AI design to an Investigational New Drug (IND) application (or foreign equivalent) in approximately two years, with a total investment of about $15 million per program. This compares to an industry average of 4-6 years at a cost greater than $50 million. Absci's lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life for patient-friendly dosing. ABS-201 is being developed for two indications: androgenetic alopecia (AGA) and endometriosis. Androgenetic alopecia, also known as pattern hair loss (PHL), affects approximately 80 million people in the United States. ABS-201 is currently being evaluated in the HEADLINE™ Phase 1/2a clinical trial (NCT07317544) for AGA. The company has dosed the first three single ascending dose cohorts with a favorable safety profile to date, and interim proof-of-concept data, including exploratory efficacy endpoints, are expected in the second half of 2026. For endometriosis, a chronic condition estimated to affect approximately 10% of women of reproductive age worldwide, Absci plans to initiate a Phase 2 clinical trial of ABS-201.

Absci Corp (NASDAQ:ABSI) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 21 items for ABSI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 9 rated 8 or above. Recent SEC coverage for ABSI spans 8-K, 10-Q, 424B5, DEF 14A.

Recent high-impact activity:

  • Absci Q3 Revenue Misses by Half; Hair-Loss Data Readout Set for December
  • Absci Q3 Revenue Misses Estimates by More Than Half at $304K
  • Absci Q2 Revenue Misses by 73%, Loss Widens; Cash Runway Extended to H2 2028
  • Absci Q2 2026: Cash Runway Extended to H2 2028, ABS-201 Data Readouts on Track
  • Absci Q2 2026: Cash Runway Extended to 2H 2028, Key Clinical Milestones on Track

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$2.8M
Net Income
-$115.18M
Diluted EPS
-$0.84
Op. Cash Flow
-$92.92M
Free Cash Flow
-$94.03M
Operating Income
-$120.32M
Cash & Equivalents
$20.02M
Debt / Equity
0.00×
Net Margin
-41.14×
Shares Outstanding
136.78M sh
Source: 10-K · filed 2026-03-24 · accession 0001672688-26-000068

Short Interest & Short Volume

9.06 days to cover

FINRA reported short interest of 35,838,218 shares in ABSI as of the October 30, 2026 settlement, a 3.2% decrease from the prior period — about 9.1 days to cover at its recent average daily volume. On November 20, 2026, 56.4% of ABSI volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)35,838,218 shares as of October 30, 2026
Change vs prior period▼ 3.2%
Days to cover9.06 at avg daily volume of 3,955,832
Daily short volume (FINRA facilities)56.4% of 1,662,956 shares on November 20, 2026
5-day average short volume49.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for ABSI, detected from its recent SEC filings · based on capital-structure filings through 2026-06-24.

1 recent capital raise1 shelf registration

$100 Million Capital Raise · Strategic Investor Participation

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$7.61 +1.33% today
52-week range · as of 2026-11-12 $2.24 – $12.54
Market cap
$1.3B
Volume
4.7M (1.1× avg)
3-mo avg 4.3M
Live data · 2026-11-21 22:44 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ABSI - Latest Insights

ABSI
Nov 12, 2026, 7:11 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.85
Real-time Price: $7.61 info
Change: -$2.24 (-23%) info
Market Cap: $1.297B info
ABSI
Nov 12, 2026, 7:06 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $9.74
Real-time Price: $7.61 info
Change: -$2.13 (-22%) info
Market Cap: $1.297B info
ABSI
Aug 11, 2026, 4:14 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $8.35
Real-time Price: $7.61 info
Change: -$0.7381 (-9%) info
Market Cap: $1.297B info
ABSI
Aug 11, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $8.02
Real-time Price: $7.61 info
Change: -$0.4101 (-5%) info
Market Cap: $1.297B info
ABSI
Aug 11, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.40
Real-time Price: $7.61 info
Change: -$0.790 (-9%) info
Market Cap: $1.297B info
ABSI
Jun 24, 2026, 4:31 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $10.08
Real-time Price: $7.61 info
Change: -$2.47 (-25%) info
Market Cap: $1.297B info
ABSI
Jun 24, 2026, 4:30 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $10.08
Real-time Price: $7.61 info
Change: -$2.47 (-25%) info
Market Cap: $1.297B info
ABSI
Jun 24, 2026, 7:20 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $9.00
Real-time Price: $7.61 info
Change: -$1.39 (-15%) info
Market Cap: $1.297B info
ABSI
Jun 24, 2026, 6:32 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.64
Real-time Price: $7.61 info
Change: -$0.030 (-0.39%) info
Market Cap: $1.297B info
ABSI
Jun 24, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $7.64
Real-time Price: $7.61 info
Change: -$0.030 (-0.39%) info
Market Cap: $1.297B info
ABSI
May 07, 2026, 4:24 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $5.55
Real-time Price: $7.61 info
Change: +$2.06 (+37%) info
Market Cap: $1.297B info
ABSI
May 07, 2026, 4:21 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.52
Real-time Price: $7.61 info
Change: +$2.09 (+38%) info
Market Cap: $1.297B info
ABSI
May 07, 2026, 4:05 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $5.66
Real-time Price: $7.61 info
Change: +$1.95 (+34%) info
Market Cap: $1.297B info
ABSI
Apr 22, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $3.67
Real-time Price: $7.61 info
Change: +$3.94 (+107%) info
Market Cap: $1.297B info
ABSI
Apr 14, 2026, 9:00 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $3.14
Real-time Price: $7.61 info
Change: +$4.47 (+142%) info
Market Cap: $1.297B info
ABSI
Mar 24, 2026, 4:30 PM EDT
Filing Type: 10-K
Importance Score:
7
Price at Filing: $2.84
Real-time Price: $7.61 info
Change: +$4.77 (+168%) info
Market Cap: $1.297B info
ABSI
Mar 24, 2026, 4:28 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.84
Real-time Price: $7.61 info
Change: +$4.77 (+168%) info
Market Cap: $1.297B info
ABSI
Mar 24, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.81
Real-time Price: $7.61 info
Change: +$4.80 (+171%) info
Market Cap: $1.297B info
ABSI
Mar 06, 2026, 4:20 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.38
Real-time Price: $7.61 info
Change: +$5.23 (+220%) info
Market Cap: $1.297B info
ABSI
Mar 03, 2026, 8:04 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $2.68
Real-time Price: $7.61 info
Change: +$4.94 (+184%) info
Market Cap: $1.297B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets